Table 4.
Adverse events in objective blood tests during the treatment and sequelae at the 10th week in patients between group I and group II
| Group I (AmB+ | Group II (AmB+ | P-value | |
|---|---|---|---|
| Fluconazole + 5-FC) | Fluconazole + 5-FC + VPS) | ||
| Adverse events (n, %) | (n = 27) | (n = 39) | |
| Hypokalemia | 13 (48.1%) | 20 (51.3%) | 0.804 |
| Transaminase elevation | 14 (51.9%) | 15 (38.5%) | 0.285 |
| Renal impairment | 5 (18.5%) | 12 (30.8%) | 0.267 |
| Hematological impairment | 5 (18.5%) | 14 (35.9%) | 0.128 |
| Sequelae | (n = 27) | (na = 36) | |
| Headache | 9 (33.3%) | 9 (25.0%) | 0.395 |
| Dizziness/vertigo | 2 (7.4%) | 5 (13.9%) | 0.465 |
| Hemiparesis | 4 (14.8%) | 5 (13.9%) | 0.850 |
| Visual | 8 (29.6%) | 6 (16.7%) | 0.184 |
| Auditory | 1 (3.7%) | 7 (19.4%) | 0.077 |
| Seizure | 3 (11.1%) | 2 (5.6%) | 0.387 |
a One patient was lost to -follow-up and two patients were death at the 10th week in Group II